Nanomaterial-induced autophagy: a new reversal MDR tool in cancer therapy?

Elisa Panzarini1, Luciana Dini

  • 1Department of Biological and Environmental Science and Technology (Di.S.Te.B.A.), University of Salento , 73100 Lecce, Italy.

Insights

Multidrug resistance (MDR) in cancer hinders chemotherapy. Autophagy and nanomaterials (NMs) offer new strategies to overcome MDR by modulating cancer cell death and drug delivery, potentially enhancing therapeutic outcomes.

Area of Science:

  • Oncology
  • Nanomedicine
  • Cellular Biology

Background:

  • Cancer therapies primarily aim to kill malignant cells, with apoptosis being the main exploited mechanism.
  • Multidrug resistance (MDR) is a significant limitation in cancer treatment, enabling cells to resist chemotherapy through various mechanisms.
  • Autophagy and nanosized drug delivery systems (DDSs) are emerging as alternative strategies to combat MDR.

Purpose of the Study:

  • To review recent literature on the interplay between multidrug resistance (MDR) reversal, nanomaterials (NMs), and autophagy.
  • To explore the potential of NMs and autophagy modulation as strategies to overcome MDR in cancer therapy.
  • To hypothesize the role of NM-induced autophagy in counteracting MDR.

Main Methods:

  • Literature review of recent publications on MDR reversal, NMs, and autophagy.
  • Analysis of mechanisms by which autophagy and NMs can circumvent MDR.
  • Examination of the cellular response of autophagy to NMs.

Main Results:

  • Nanosized DDSs can accumulate chemotherapeutics at target sites and control drug release.
  • Autophagy can promote cancer cell death or sensitize cells to anticancer drugs, thus overcoming MDR.
  • Autophagy is a common cellular response to NMs, suggesting its potential exploitation in nanomedicine.

Conclusions:

  • Modulation of autophagy, particularly NM-induced autophagy, plays a pivotal role in counteracting MDR.
  • Combining NMs with autophagy modulation presents a promising therapeutic strategy for overcoming MDR in cancer.
  • Further research into NM-autophagy interactions is crucial for developing effective nanomedicine therapies against MDR cancer.

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.6K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.2K
Autophagy01:27

Autophagy

Autophagy is a self-digesting process by which a cell protects itself from threats both within and outside the cell, ranging from abnormal proteins to invading bacteria. In this process, obsolete components of the cell and invading microbes are degraded by hydrolytic enzymes active in an acidic environment of the lysosomal lumen.
An autophagic pathway consists of a series of signaling events activated in response to diverse stress and physiological conditions such as food deprivation,...
5.0K
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
3.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K